上尿路尿路上皮癌围手术期辅助化疗的研究进展

Research progress of perioperative adjuvant chemotherapy for upper tract urothelial carcinoma

上尿路尿路上皮癌(UTUC)发病隐匿、恶性程度较高、预后差。既往UTUC的疾病特异性生存率(CSS)未得到改善,随着国内外医学界对UTUC诊疗认识不断提高,研究发现围手术期辅助化疗可以改善UTUC患者的肿瘤控制结局,其包括术后的全身系统化疗及膀胱灌注化疗以及术前新辅助化疗,但针对患者个体化诊疗方案目前还有待商榷,本文就UTUC围手术期辅助化疗的研究进展做一综述。

Upper tract urothelial carcinoma(UTUC) has an occult onset, a high degree of malignancy and a poor prognosis. In the past, the cancer specific survival(CSS) of UTUC has not been improved. With the increasing awareness of UTUC diagnosis and treatment in medical circles at home and abroad, it has been found that perioperative adjuvant chemotherapy can improve the tumor control outcome of patients with UTUC.It includes postoperative systemic chemotherapy, intravesical chemotherapy of bladder and preoperative neoadjuvant chemotherapy. However, the individualized diagnosis and treatment scheme for patients remains to be discussed. The research progress of perioperative adjuvant chemotherapy of UTUC at the present stage is reviewed in this article.